Both ev3 business segments continue to show excellent growth
Our performance in 2009 reflects continued sales expansion across our neurovascular and peripheral vascular businesses. Our neurovascular business achieved year-over-year sales growth of 28%, outpacing the market growth rate by approximately two times. In our peripheral vascular business, we realized year-over-year sales growth of 4%, and legacy peripheral vascular product growth of 8%. We stabilized our plaque excision business, which is now well-positioned for improved growth in 2010. We are particularly gratified that these increases indicate that more and more patients around the world are benefiting from our best-in-class endovascular therapies.
Print
